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Candida albicans is a fimgus that may cause mild to fatal infections in people
with compromised immune systems. Patients undergoing chemotherapy or radiation
therapy as a result of cancer, or those infected with AIDS, frequently develop Candida
infections. Candida albicans is part of the normal human flora, but invasive or deep
Candidiasis is usually fatal and the less serious forms are often persistent and recurring.
C. albicans exists as cellular yeast, or benign budding form, and as a filamentous form.
The filamentous form is associated with pathogenicity and has the ability to penetrate
tissues. This transformation appears to be controlled by the Ras protein. In vitro,
filament formation can be caused by serum induction or nitrogen starvation.
Ras proteins are small GTP-binding proteins involved in signal transduction. Ras
proteins are post translationally prenylated. Prenylation ofRas involves the addition of a
famesyl group at a cysteine residue localized four amino acids from the C-terminus.
It is then modified by removal of the last three amino acids and methylation of the newly
exposed famesyl-cysteine residue. Ras is considered to be inactive if it is not prenylated.
IfRas prenylation is blocked it may prevent the formation of filamentous Candida
albicans. The objective of this study is to determine which proteins in Ras signaling
pathway are important for the formation of filaments.
In the presence of inhibitors of the mevalonate, alternative IPP, and MAPK
pathways, C. albicans cells were grown on solid media (YPD and spider) for four days.
These results show that an inhibitor of the alternative IPP pathway caused little or no
effect on the growth of C. albicans or on the formation of filaments. On the other hand,
Mevastatin, an inhibitor of the mevalonic acid pathway to IPP, caused significant
inhibition ofboth growth and the formation of filaments. An inhibitor ofMEK, a protein
in the MAP-Kinase pathway, caused little or no inhibition ofgrowth ofC. albicans but
caused some inhibition of filament formation at higher concentrations. ThisMEK
inhibitor does not appear to completely inhibit yeast to filament transformation.
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Candidiasis is a growing epidemic among patients with compromised immune
systems. Patients imdergoing radiation therapy, anthrax therapeutics or those infected
with AIDS are subject to Candida infection.Candida albicans is the most common
species ofCandida yeast involved in this type of infection. It is part of the normal
human flora and helps control harmful bacteria in the intestinal tract.^’^ Candida
albicans is commonly the cause ofvaginal yeast infections in women when antibiotics
are taken.'* This organism can become invasive when drugs are given that impinge on
the immune system.^ '* Candida albicans is attracted to sugars and pH changes in the
digestive system.^’'*’^
Candida albicans can exist in two forms: a benign budding or cellular yeast form,
and a filamentous form.^ When it is in the filamentous form, Candida albicans can
penetrate mucous and intestinal walls allowing microscopic holes to form, permitting
entry to these areas. C. albicans can further penetrate into organ tissue causing fatality
to its host.^ Drugs currently used to try to control Candidiasis are not completely
successful. Two problems exist: Candida can become resistant to the drug, or the drug
toxicity to the patient can be too high and hence cannot be administered for a long period
of time.* Another problem is that most drugs can only be administered
intravenously; if taken orally the drug is broken down in the digestive system.^
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The ideal drug to treat Candidiasis would be capable ofbeing ingested orally and
be less likely to cause Candida to develop resistance. The objective of this study is to
begin to determine which pathways are pertinent in the development of filaments in
Candida albicans in order to develop new treatment strategies for Candidiasis. The
chosen pathways are the mevalonate pathway to IPP, the alternate IPP pathway, and the
MAPK pathway. All of these pathways are involved in the Ras signaling pathway. Ras
signaling begins when this small GTP- binding protein is activated by prenylation.
Activationmay occur via the mevalonate pathway or the alternate IPP pathway.**^’”’*^
TheMAPK pathway converts receptor signals from the Ras signaling cascade into a
variety of signals.
Part of this investigation consisted of streaking C. albicans cells onto solid media
in the presence and the absence of inhibitors of the aforementioned pathways. The edges
of the colonies were observed for filamentous formation after four days. In order to
investigate the effect of the inhibitor on Candida albicans cells in liquid media in the
cellular or budding form, the cells were incubated in the presence or absence of the
inhibitors and the turbidity measured by optical density at 600 nm. To determine the
effects ofmevastatin on filament formation, C. albicans cells were incubated in the
presence or absence of the inhibitor in the presence of serum. The cellular yeast form
and the filamentous form of the organism were then separated and a protein assay was
performed which gave a relative measurement of the amount ofprotein in both forms.
CHAPTER!
LITERATURE REVIEW
2.1 Candidiasis and the Morphogenesis of C. albicans
Candida albicans is a fungus that may cause mild to fatal infections in people
with compromised immune systems, such as patients undergoing chemotherapy or
radiation therapy as a result of cancer or those affected by AIDS.* Candida albicans is
part of the normal human flora, but invasive or deep Candidiasis is usually fatal and the
less serious forms are often persistent and reoccurring. C. albicans exists as cellular
yeast, or benign budding, and a filamentous form^; cells in the yeast form divide
mitotically by budding, forming two independent daughter cells.**’*^’*’ Filamentous
growth ofCandida albicans is initiated by an asymmetric cell division in which a round
yeast cell divides to produce an elongated cell; this process repeats to form a filament.*^
The filamentous form is associated with pathogenicity and is able to penetrate tissues.
During growth of filaments, the cells do not separate after nuclear division but remain
physically associated.*^’ *®’ *^ Under some conditions distinct cell walls form between the
daughters, but remain attached to form chains of elongated cells called pseudohyphae.
Under other conditions no constrictions form at cell junctions after division and a
smooth tube called a hypha is produced. The filamentous transformation in vitro can be
induced by serum in the case ofhyphae and appears to be controlled by the
Ras protein. *^’*^’*^ Other conditions can also produce hyphae or psuedohyphe.*^’ *^
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2.2 Protein Prenylation of the Ras protein
Ras proteins are small GTP-binding proteins involved in signal transduction. In
response to a variety of extracellular signals Ras is converted from an inactive GDP-
bound form to an active GTP-bovmd form.*^’ The Ras protein signal in C. albicans has
been shown to be important for formation of filaments in that organism.’^ In other
organisms the Ras protein must be prenylated to transmit extracellular signals. Ras
proteins can stimulate the mitogen-activated protein kinase (MAPK) cascade.**^
Ras proteins are prenylated post-translationally. Protein prenylation involves the
attachment of a famesyl group, a C-15 isoprenoid, or a geranylgeranyl group, a C-20
isoprenoid. Prenylation ofRas in most cases involves the addition of a famesyl group at
a cysteine residue located four amino acids from the C-terminus. It is then fiirther
modified by removal of the last three amino acids and methylation of the newly exposed
famesyl-cysteine residue. Ras has be shown to be inactive in other organisms if
prenylation does not occur.*® Prenylation ofRas is associated with protein-protein
interactions ’ ’ and membrane binding. Hence, ifRas prenylation is blocked, it
may prevent the formation of filaments in C. albicans.
2.3 Stating the Problem
Studying the morphogenesis ofCandida albicans has been a growing interest
among researchers. Since this yeast can be a fatal pathogen and the filamentous form is
associated with disease, it is important to understand the mechanism of filamentous
formation and find means ofpreventing the effect. Current drugs used for Candida
infections are either toxic and cannot be used for a long period of time, or the yeast can
develop resistance or both, rendering the dmg less useful.®’’’ ® One of the goals of this
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research is to determine which pathways are essential for filamentous development.
There are three pathways of interest for this study, which potentially had some
involvement in the formation of filaments: (1) the mevalonate pathway which gives rise
to famesyl pyrophosphate, a precursor of the prenyl group ofRas, (2) the alternate IPP
pathway which can also produce famesyl pyrophosphate, and (3) the MAPK pathway,
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which is utilized for transcytoplasmic signaling to the nucleus. ’
2.4 Pathways and Inhibitors
2.4.1 Mevalonate Pathway is Inhibited by Mevastatin
The mevalonate pathway, (scheme 1), has been shown to be important in cell
proliferation.^^ This pathway is a precursor for lipidated proteins, such as famesylated
Ras, and involves 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reduction to
mevalonate by HMG-CoA reductase. Mevalonate is then converted to isopentenyl
diphosphate (IPP) with mevalonate 4-phosphate as an intermediate.** Some of the pool
of IPP is isomerized to dimethylallylpyrophosphate and these two molecviles are then
condensed to form geranyl pyrophosphate. An additional molecule of IPP is
enzymatically condensed with geranyl-PP to form FPP, the precursor of the famesyl














25,26Scheme 1. Mevalonic Acid Pathway to Prenylated Proteins.
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The mevalonate pathway can be inhibited by statins, competitive inhibitors that
block the activity ofHMG-CoA reductase. If filamentous formation is dependent on this
pathway, then addition of a statin inhibitor should prevent the morphogenic
transformation ofC. albicans from a cellular yeast to a filamentous form. Mevastatin,
(figure 1), acts as a potent inhibitor ofHMG-CoA reductase preventing a series of
reactions leading to the production ofFPP. Mevastatin was chosen because it is cost
effective and can be used as amodel for other non-toxic HMG-CoA reductase
inhibitors.^^’^^
HO
Figure 1. Structure ofMevastatin
Famesol, (figure 2), is a liquid alcohol, which has been shown, in mammalian
cells, to be utilized in protein prenylation. Famesol has been shown to be converted to
FPP through successive monophosphorylation in tobacco cells, and at least two CTP-
*ya
mediated kinases have been found. C. albicans cells were incubated in the presence of
famesol and mevastatin. The addition of famesol may permit the formation ofFPP in
the absence of the mevalonate pathway. If this does not occur it can be suggested that C.
albicans does not convert famesol to FPP when the mevalonate pathway is inhibited.
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Figure 2. Structure ofFamesol
2.4.2 Alternative IPP Pathway is Inhibited by Fosmidomycin
In eubacteria, algae and some plants isoprenoids such as IPP were found to
develop via the I-deoxy-D-xyluIose 5-phosphate (DOXP) pathway or the non-
mevalonate pathway, (scheme 2). In this alternative IPP pathway glyceraldehyde 3-
phosphate and pyruvate condense to form DOXP, which is then converted to 2-methyl-D-
erythritol 4-phosphate. The conversion ofDOXP is a result of two enzymes, DOXP
synthase and DOXP reductoisomerase.** DOXP is converted to three different
isoprenoids, and then converted to IPP. The conversion of IPP to geranyl diphosphate
















Scheme 2. Alternate IPP Pathway
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Fosmidomycin (figure 3) is currently used to treat malaria, and is an inhibitor of the
DOXP pathway." IfRas prenylation is dependent on this pathway, then the formation of
filaments should be prevented in the presence of this inhibitor.
OH HO
OH
Figure 3. Structure ofFosmidomycin
2.4.3 MAPK Pathway is Inhibited by PD098059
The MAPK pathway (scheme 3) can be described as a signaling module that
converts receptor signals into a variety of outputs. It participates in transcytoplasmic
signaling to the nucleus, fi’om which transcription of specific genes is induced through
phosphorylation and activation of transcription factors. There are fourMAPKs known in
yeast and three in vertebrates. They are activated through threonine/tyrosine
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Scheme 3. ProposedMAPK pathway in Candida yeast.^^ Protein kinases are in
the rectangular box and the corresponding genes are in ovals.
In eukaryotic cells the MAPK pathway has been shown to control cell pro¬
liferation;** since Candida albicans morphogenesis is amitotic response,^®’inhibition
of this pathway could prevent the formation of filaments. In order to evaluate this
further, yeast cells ofC. albicans strain H-317 were exposed in the presence and absence
of serum to a synthetic MEK inhibitor PD098059 [2-(2’-amino-3’-methoxyphenyl)-





Figure 4. Structure ofPD098059
2.5 Objective
In order to investigate the roles of the mevalonate pathway, the alternative IPP
pathway, and the MAPK pathway in the development of filamentous C. albicans,
inhibitors of these pathways were introduced in liquid and solid media solution. C
albicans cells were incubated in the presence and absence of inhibitors in vogels media.
The turbidity was measured in order to evaluate the affect of inhibitors on cell
proliferation. Incubation ofcells on solid media in the presence of serum or on nitrogen
starved media presented visual results on filamentous transformation. C. albicans cells
were exposed to mevastatin in liquid media in the presence of serum then incubated O.N.
Cellular and filamentous fiuctions were separated using a mesh screen. Protein






The H-317 strain ofC. albicans, a clinical isolate, obtained from the Centers for
Disease Control and Prevention, was used in all experiments. The yeast was inoculated,
in the budding or cellular yeast form, at room temperature in YEPD media [1% w/v yeast
extract (DIFCO), 2% w/v Bacto peptone (DIFCO), 2% w/v dextrose (Fisher Scientific)]
or Vogel’s media [2% Vogel’s solution, 2% biotin, 2% vitamin solution, 2% inositol, and
10% glucose]. Working cultures were prepared from a stock culture at a 1/1000 fold
dilution using YEPD media or Vogel’s media. The culture was incubated O.N. at room
temperature.
3.1.2 Solid Media and Inhibitors
Solid media growth on YEPD[ 1% w/v yeast extract (DIFCO), 2% w/v Bacto
peptone (DIFCO), 2% w/v dextrose (Fisher Scientific), 1% agar (DIFCO)] or Spider
media [1% nutrient broth (DIFCO), 1% mannitol (Sigma), 2% potassium phosphate
(Fisher Scientific) and 1% agar (DIFCO)]. The inhibitors introduced in assays were:
Mevastatin, purchased from Cal-Biochem, Fosmidomycin, purchased from Molecular
Probes andMEK Inhibitor (PD098059), purchased from Cal Biochem.
13
14
3.13 Assays and Equipment
A protein assay kit was purchased from Biorad. Absorbance was detected using a
Beckman DU 650 spectrophotometer. All cultures were centrifiiged using a Beckman
Centrifuge GS-R at 2000 rpm. Solid media plates were incubated in a Fisher Oven at the
indicated temperatures. Photomicrographs were taken using a 35 mm camera attached to
an inverted microscope.
3.1.4 Preparation ofSolutions
Phosphate Buffered Saline (PBS) [140 mM NaCl, 3 mM KCl, 8.6 mM NaHP04,
2.3 Mm KH2PO4, adjusted to pH 7.4 with HCl)] was used for dilutions and as a wash
buffer in the assays. Bovine Serum Albumin (BSA) was purchased from Sigma. DMSO
was used as a vehicle for PD98059 and was purchased from Fisher Biotech. Famesol (all
trans-Famesol 96%) was purchased from Aldrich Chemical Company.
3.2 Experimental Methods
3.2.1 Cellular Yeast Growth
Ten |al ofC. albicans cells were inoculated in 10 ml ofVogel’s media and
incubated O.N. at room temperature. The overnight culture was further diluted 1/10.
Dilutions of the cells were made for each inhibitor concentration in triplicate and
incubated O.N. at room temperature. Each tube was vortexed and then 100 |li1 of drug
treated cells were diluted with 900 |iil ofVogel’s media. The turbidity of the solution
was measured at 600 nm. The average results were plotted as absorbance verse drug
concentration. The standard deviation was calculated and depicted on the graphs by ±
bars.
3.2.2 Solid Growth Media
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A working culture was prepared by inoculating 10 pi of C. albicans cells in 10 ml
ofYEPD and incubated O.N. at room temperature. A 2 ml volume ofYEPD or Spider
media was prepared with inhibitor at the indicated concentrations. For serum induction
10% serum was added after the media was autoclaved. The media was poured into 2 ml
wells for each inhibitor concentration and a control, vehicle solution for inhibitors, and
Q
then the media was allowed to solidify. Serial dilutions of the cultures obtained 10
cells, which were added to each well and incubated four days at the following
temperatures: 37*C for YPD; 30'C for spider media. Pictures were taken of the colony’s
edge on the fourth day using a 35 mm camera on an inverted microscope at a
magnification of lOX.
3.23 C albicans Filamentous Transformation and Separation Assay
Drug treatment and serum induction. A 1/1000 fold dilution culture in YPD was
prepared fi*om C. albicans C. albicans stock and incubated O.N. at room temperature.
Drug dilutions were made and cultures were inoculated at a 1/10 dilution in Vogel’s
media in the absence of serum. Each inhibitor concentration was prepared in triplicate
along with a vehicle control. The cultures were incubated at room temperature for two
hours. After the two-hour incubation 500 pi of the drug treated cells was inoculated into 4
ml of 10% serum and PBS solution plus another dose of the drug. The new cultures were
incubated O.N. at 37°C.
Washing ofcultures. Fivemilliliters ofPBS was added to each culture and
vortexed for a few seconds; the cultures were then centrifuged at 2000 rpm for 10
minutes. After centrifugation, the supernatant was discarded and the pellet was saved.
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This washing procedure was repeated three more times with 10 ml aliquots ofPBS, in
order to remove the serum proteins.
Mesh screen separation and cell disruption. Filamentous and cellular yeast forms
ofC. albicans were separated by passage through a polypropylene 105 |am mesh screen
(Fisher Scientific) into a 50 ml falcon tube using 100 |li1 aliquots ofPBS up to 10 ml.
Three grams of glass beads (0.4-0.6 mm diameter) were added to each falcon tube and
vortexed for 2 minutes to disrupt cell and release proteins in each fraction.
Bio Rad assay andprotein absorbance. All cxxltures were then centrifuged at
2000 rpm for 10 min to pellet cell debris and beads. After centrifugation, 800 pi aliquots
of supernatant were transferred to disposable glass tubes. For each glass tube, 200 pi of
Bio Rad dye was added and the absorbance was recorded at 595 nm. A graph of
absorbance vs. drug dilution was plotted using the triplicate average and standard
deviations were calculated and depicted as ± bars.
CHAPTER 4
RESULTS AND DISCUSSION
4.1 C albicans Cells Exposed to Inhibitors in Liquid Media.
In order to determine if the inhibitors used prevented filamentation ofC. albicans
rather than cell proliferation, C. albicans cells were exposed to inhibitors in liquid YPD
at a 1/10 dilution in the absence of serum and incubated overnight. The cell growth was
determined by evaluating the turbidity, by measuring the optical density at 600 nm.
The first graph (figure 5) shows that when mevastatin is introduced at
concentrations of 0.6 |liM, 6 |jM, and 60 |liM, there is a significant decrease in absorbance,
which is expected since mevastatin is a known inhibitor of several important pathways.
Mevastatin was also introduced at broader concentrations: 15 pM, 20 pM, 40 pM, and
60 pM. The results show (figure 6) that the turbidity decreases progressively from 15
pM to 60 pM significantly.
When C. albicans cells are exposed to Fosmidomycin and a synthetic MEK
inhibitor, PD098059, the results were quite different. The turbidity of cells exposed to
Fosmidomycin at IpM, and lOpM are not significantly different, (figure 7). Cells
exposed to PD098059 did not show any significant decrease or increase in the turbidity of
the cells (figure. 8).
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Figure 5. Cellular Growth of C. albicans Cells in the Presence ofMevastatin in Vogel’s
Media (0.6,6,60 )jM). Bars represent ± standard deviation.
Figure 6. Cellular Growth ofC. albicans Cells in the Presence ofMevastatin in Vogel’s
Media (15,20,40,60 |aM). Bars represent ± standard deviation.
Figure 7. Cellular Growth of C. albicans Cells in the Presence of Fosmidomycin













□USO Control IOOmM 200mM
Drug Dilutions
400^M
Figure 8. Cellular Growth in the Presence ofPD089059 in Vogel’s Media.
Bars represent ± standard deviation.
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4.2 C albicans Exposed to Inhibitors on Solid Media
4.2.1 Effects ofMevastatin
Rasprenylation appears to be dependent on the mevalonatepathway in
C. albicans. The Ras protein has been shown to be involved in yeast morphogenesis and
in other organisms Ras has been shown to be inactive when it is not prenylated. An
inactive Ras protein will not initiate the signaling cascade for morphogenesis to occur in
serum induced media. With this in mind C. albicans cells were exposed to inhibitors of
the mevalonate dependent pathway and the alternative IPP pathway both ofwhich
potentially lead to prenylated proteins. IfC. albicans morphogenesis is dependent on
either of these pathways filaments should not form when incubated in the presence of the
inhibitors of the respective pathways.
Cells were incubated on solid serum-induced YPD media and nitrogen deficient
media for four days. Figures 9 and 10 show that when C. albicans cells were exposed to
Fosmidomycin a synthetic inhibitor of the alternative IPP pathway, at concentrations of
1 pM and 10 pM, filaments formed in both the vehicle control and the inhibitor treated
samples. There is a noticeable difference between the types of filaments grown on
serum-induced YPD media (figure 9) and spider media (figure 10). On serum-induced
YPD media the filaments appear to be in the hyphae, on spider media it appears that
pseudohyphae structures are formed.
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Figure 9. C. albicans Cells Incubated Serum-Induced YPD Media in the Presence of
Fosmidomycin. A) Water control, B) 10 )liM, C) 1 |iM
Figure 10. C. albicans Cells Incubated on Spider Media in the Presence of
Fosmidomycin. A) Water control, B) 10 |uM, C) 1 |aM
When C. albicans cells were exposed to mevastatin, inhibitor of the mevalonate
dependent pathway, the results were quite different. The C. albicans cells were first
grown on YPD + serum and spider solid media with a vehicle control and 60 pM of
mevastatin for four days. Figure 11 and 12 show that filaments formed on the PBS
control, and the cells exposed to 60 |uM ofmevastatin had a smooth edge on the colony,
without any sign of filaments present. These results led to further evaluation of the
inhibitor at lower concentrations, 0.6 pM and 6 pM (figures 13 and 14).
Figure 11. C albicans Cells Incubated on Serum-Induced YPD Media in the Presence of
Mevastatin (60 pM). A) PBS Control, B) 60 pM
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Figure 12. C. albicans Cells Incubated on Spider Media in the Presence of
Mevastatin (60 juM). A) PBS control, B) 60 pM
Figure 13. C albicans Cells Incubated on Serum-Induced YPD Media in the Presence of
Mevastatin (0.6 pM, 6 pM, 60 pM). A) PBS control, B) 60 pM, C) 6 pM,
D) 0.6 pM
Figure 14. C. albicans Cells Incubated on Spider Media in the Presence of
Mevastatin (0.6 pM, 6pM and 60 pM). A) PBS control, B) 60 pM, C) 6pM,
D) 0.6 pM
4.2.2 Effects of Famesol in the Presence of 60 pM Mevastatin
The introduction offarnesol does not reverse the affect ofmevastatin on
filamentousformation. Since the mevalonate pathway appears to be the relevant pathway
leading to protein prenylation ofRas in C albicans based on the above inhibition data,
further evaluation of the effects of the inhibitor of this pathway on C albicans
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morphogenesis was examined. C. albicans eells were treated with 60 pM of
mevastatin. The introduction of famesol had the potential to reverse the effects of
mevastatin ifC albicans cells utilize the famesol to form famesylpyrophosphate. In
figures 15 and 16, all cells were treated with 60 pM ofmevastatin plus the indicated
concentrations of famesol; 1 pM, 10 pM, and 100 pM, filaments did not form, suggesting
that the yeast cells do not convert famesol into FPP when the mevalonate pathway is
inhibited.
Figure 15. C. albicans Cells Incubated on Serum-Induced YPD (Mevastatin and
Famesol). A) PBS and Water control B) 60 pM Mevastatin and
100 pM famesol, C) 60 pM Mevastatin and 10 pM famesol,
D) 60 pM Mevastatin and 1 pM famesol
Figure 16. C. albicans Cells Incubated on Spider Media (Mevastatin and Famesol).
A) PBS and Water control, B) 60 pM Mevastatin and 100 pM famesol,
C) 60 pM Mevastatin and 10 pM famesol, D) 60 pM Mevastatin
and 1 pM famesol
4.2.3 Effects ofMEK Inhibitor on Filamentous Formation
MEK inhibitor did not entirelypreventfilamentformation. PD098059 is a
synthetic inhibitor ofMEK protein in the MAPK pathway. This pathway receives signals
from the Ras protein and develops them as outputs to the nucleus. If this pathway is
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inhibited outputs which trigger filament transformation may be prevented. The results
show (figures 17 and 18) that the inhibition of the MEK did not completely prevent the
formation of filaments. At 100 |liM, 200 pM and 400 pM ofPD098059 filaments appear
at the edge of the colonies in both serum induced YPD and spider media. As the
concentration of the MEK inhibitor increases it appears the amount of filaments that
extend from the colony’s edge decreases as compared to the DMSO vehicle control.
Figure 17. C. albicans Cells Incubated on Spider Media in the Presence ofMEK
Inhibitor. A) 100 pM, B) 200 pM, C) 400 pM
Figure 18. C. albicans Cells Incubated on Serum-Induced YPD Media in the Presence of
MEK Inhibitor A) 100 pM, B) 200 pM, C) 400 pM
4.3 Additional Effects ofMevastatin on C. albicans Morphogenesis
The separation assay was performed as described in the methods section. This
technique has been recently developed and has a fair amount of error associated with it.
The graph (figure 19) shows that the filamentous form of the Candida albicans decreased
significantly when exposed to 6 pM and 60 pM ofmevastatin. The other graph (figure
20) depicts the effect ofmevastatin on the cellular form of C. albicans strain after
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separation and gives an idea ofhow much yeast has not undergone filament
transformation. The protein absorbance of the 60 pM fraction is almost equivalent to that
ofthe control. The 0.6 pM and 6 pM fractions were lower in absorbance than the control
fraction. The average standard deviations of the fractions are depicted on the graph. The
graphs are used as a measurement of relative protein absorbance since
filaments tend to aggregate around the yeast form increasing the absorbance of filament
protein and decreasing the absorbance for the cellular protein.
Figure 19. Effect ofMevastatin on Filament Formation in C. albicans Cells. Incubated
in serum-induced media at 37°C and indicated concentration of inhibitor.
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Figure 20. Effect ofMevastatin onC albicans Cellular Growth after Separation.




Fosmidomycin does not have a significant effect on cellular yeast growth in liquid
media in the absence of serum; likewise PD098059 does not significantly increase or
decrease cellular yeast growth in liquid media in the absence of serum. Mevastatin has
been shown to be the only potent inhibitor of C. albicans cellular yeast growth, which is
consistent with studies done with this inhibitor in mammalian cells.
Filament formation in C. albicans was found to be inhibited completely by
60 pM mevastatin. At lower concentration ofmevastatin the inhibitor did not entirely
prevent morphogenesis. When C. albicans cells were exposed to Fosmidomycin on solid
media the cellular to filament transformation occurred in a fashion indistinguishable fi'om
control. These combined results suggest that the mevalonate pathway, but not the
alternative IPP pathway, is pertinent for filament formation. It can also be suggested that
the alternative IPP pathway may not be present in C. albicans cells, alternatively the drug
may not be transported into the cells or it is not effective against the Candida enzyme.
Inhibition of the MAPK pathway prevented morphogenesis in C. albicans cells to a
degree. As shown in figures 17 and 18 the amount of filaments extending fi-om the
colonies decreased significantly as the MEK inhibitor concentration increased. These
results show that inhibition of the MAPK pathway is not completely successful at the
chosen concentrations, however an increase in dosage may be more efficient.
27
Quantitative analysis ofthe effects ofmevastatin on filament formation showed
28
that filamentous growth decreased significantly when concentration of inhibitor is
increased. The error in this procedure is >.05 and is attributed to the partial separation
and quantification of the filamentous form fi-om the cellular form of C. albicans. Since
mevastatin has been shown to prevent morphogenesis in C albicans cells, other statins
may be examined in vitro as possible therapeutics for use in the prevention of
Candidiasis.
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